ASCO Update 2003 - Highlights vom 39. Kongress der American Society of Clinical Oncology/ASCO 2003

T. Eberl; U. Graeven; M. Heike; T. Höhler; M. P. Lutz; H. Messmann; T. Seufferlein; null für die Arbeitsgemeinschaft Gastroenterologische Onkologie der

doi:10.1055/s-2003-42922

Zeitschrift für Gastroenterologie, Table of Contents

Z Gastroenterol 2003; 41(10): 1039-1045
DOI: 10.1055/s-2003-42922

Mitteilungen

ASCO Update 2003 - Highlights vom 39. Kongress der American Society of Clinical Oncology/ASCO 2003

ASCO Update 2003 - Highlights of the 39^th Meeting of the American Society of Clinical Oncology/ASCO 2003T. Eberl¹ , U. Graeven² , M. Heike³ , T. Höhler⁴ , M. P. Lutz⁵ , H. Messmann¹ , T. Seufferlein⁶ , für die Arbeitsgemeinschaft Gastroenterologische Onkologie der DGVS

¹Medizinische Klinik III, Klinikum Augsburg
²Medizinische Universitätsklinik, Knappschaftskrankenhaus, Ruhr-Universität Bochum
³Medizinische Klinik Mitte, Klinikum Dortmund
⁴Medizinische Klinik und Poliklinik, Johannes-Gutenberg-Universität Mainz
⁵Medizinische Klinik, Caritasklinik St. Theresia, Saarbrücken
⁶Abt. Innere Medizin I, Universitätsklinikum Ulm

Abstract

Full Text

References

Literatur

1 Abid L, Oukkal M, Berkane S. et al . Phase II trial with the gemcitabine and cisplatin combination in the treatment of locally advanced and metastatic gall bladder carcinoma. Proc ASCO. 2003; 22 1302
2 Ajani J A, Van Cutsem E, Moiseyenko V. et al . Docetaxel (D), cisplatin, 5-fluorouracil ccompared to cisplatin (C) and 5-fluorouracil (F) for chemotherapy-naïve patients with metastatic or locally recurrent, unresectable gastric carcinoma (MGC): Interim results of a randomized phase III trial. Proc ASCO. 2003; 22 999
3 Allum D, Cunningham D, Weeden S. Perioperative chemotherapy in operable gastric and lower oesophageal cancer: A randomised, controlled trial (the MAGIC trial, ISRCTN 93 793 971). Proc ASCO. 2003; 22 998
4 Ardalan B, Livingstone A, Fancheschi D. et al . Neoadjuvant (NAD), adjuvant (AD) treatment without radiation in patients with advanced operable adenocarcinoma of esophagus. Proc ASCO. 2003; 22 1309
5 Armanios M Y, Xu R, Forastiere D G. et al . Phase II adjuvant chemotherapy for resected adenocarcinoma of the esophagus, gastroesophageal (GE) junction and cardia (E8296): A trial of the Eastern Cooperative Oncology Group. Proc ASCO. 2003; 22 1190
6 Bedenne P M, Michel O, Triboulet J P. et al . Randomized phase III trial in locally advanced esophageal cancer: radiochemotherapy followed by surgery versus radiochemotherapy alone (FFCD 9102). Proc ASCO. 2002; 21 519
7 Bonnetain F, Bedenne P, Michel P. et al . Definitive results of a comparative longitudinal quality of life study using the Spitzer index in the randomized multicentric phase III trial FFCD 9102 (surgery vs radiochemotherapy in patients with locally advanced esophageal cancer. Proc ASCO. 2003; 22 1001
8 Bouche O, Raoul J L, Giovanini M. et al . Randomized phase II trial of LV5FU2, LV5FU2-cisplatinum or LV5FU2-irinitecan in patients with metastastic gastric or cardial adenocarcinoma (MGA): Final results of study FFCD9803. Proc ASCO. 2003; 22 1002
9 Burris H A, Moore M J, Andersen J. et al . Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol. 1997; 15 2403-2413
10 Cebon J S, Findlay M, Hargreaves C. et al . Somatostatin receptor expression and clinical effects of octreotide LAR in patients with advanced hepatocellular carcinoma. Proc ASCO. 2003; 22 1163
11 Cunningham D, Humblet Y, Siena D. et al . Cetuximab (C225) alone or in combination with irinotecan (CPT-11) in patients with epidermal growth factor receptor (EGFR)-positive, irinotecan-refractory metastatic colorectal cancer (MCRC). Proc ASCO. 2003; 22 1012
12 de Gramont A, Banzi M, Navarro M. et al . Oxaliplatin/5-FU/LV in adjuvant colon cancer: Results of the international randomized mosaic trial. Proc ASCO. 2003; 22 1015
13 Frustaci S, Bearz A, Basso B. et al . Efficacy of oxaliplatin and 5-fluorouracil in hepatocarcinoma (HCC). Proc ASCO. 2003; 22 335
14 Fujii M, Kosaki G, Tsuchiya S for the Gastric Cancer Chemotherapy Group of Japan. et al . Randomized trial of preoperative adjuvant chemotherapy using oral 5-FU in operable gastric cancer [Abstract]. Proc ASCO. 1999; 18 272
15 Fung M C, Ishiguro H, Takayama S. et al . Survival Benefit of Chemotherapy Treatment in Advanced Pancreatic Cancer: A Meta-analysis. Proc ASCO. 2003; 22 1155
16 Gibson M K, Abraham S, Wu T T. et al . Epidermal growth factor receptor, p53 mutation and pathologi c response pedict survival in patients with locally advanced esophageal cancer treated with pre-operative chemotherapy. Proc ASCO. 2003; 22 1030
17 Hamburg S, Miller W, Garcia-Vargas J. et al . Survival benefit of nolatrexed in advanced hepatocellular carcinoma (aHCC). Proc ASCO. 2003; 22 288
18 Hawkins R, Cunningham D, Soerbye H. et al . Randomized phase II trial of docetaxel plus irinotecan versus docetaxel plus 5-fluorouracil (5FU) in patients with untreated advanced gastric adenocarcinoma (AGAC). Proc ASCO. 2003; 22 257
19 Hecht J R, Ajani A, Michaeli D. et al . A multicenter phase II study of cisplatin (CDDP) and 5-fluorouracil (5-FU) in combination with G17DT immunogen in patients with locally recurrent or metastatic adenocarcinoma of the stomach or gastroesophageal junction previously untreated for advanced disease. Proc ASCO. 2003; 22 1035
20 Hegewisch-Becker S, Corovic A, Jaeger E. et al . Whole body hyperthermia (WBH, 41.8 C) combined with carboplatin and etoposide in advanced biliary tract cancer. Proc ASCO. 2003; 22 311
21 Heinemann V, Quietzsch D, Gieseler F. et al . A phase III trial comparing gemcitabine plus cisplatin vs. gemcitabine alone in advanced pancreatic carcinoma. Proc ASCO. 2003; 22 1003
22 Hsu C, Shen Y C, Yang C H. et al . Phase II study of weekly gemcitabine plus 24-hour infusion of high-dose 5-fluorouracil/leucovorin for locally advanced or metastatic carcinoma of the biliary tract. Proc ASCO. 2003; 22 1322
23 Hurwitz H, Fehrenbacher L, Cartwright T. et al . Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer (CRC): Results of a phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluorouracil, leucovorin) as first-line therapy in subjects with metastatic CRC. Proc ASCO. 2003; 22 3646
24 Ishii H, Furuse J, Nagase M. et al . Relief of jaundice by external beam radiotherapy and intraluminal brachytherapy in patients with extrahepatic cholangiocarcinoma: Results without stenting. Proc ASCO. 2003; 22 1219
25 Ishikura S, Ohtsu A, Shiaro K. et al . A phase I/II study of nedaplatin and 5-fluorouracil with concurrent radiotherapy in patients with T4 esophageal cancer: Japan Clinical Oncology Group study (JCOG9908-DI). Proc ASCO. 2003; 22 1106
26 Izzo F, Marra P, Beneduce G. et al . Phase I/II testing of pegylated arginine deiminase in subjects with hepatocellular carcinoma. Proc ASCO. 2003; 22 1474
27 Jacobson S D, Alberts S R, Mahoney M R. et al . Phase II trial of gemcitabine (Gem), 5-fluorouracil (5FU), and leucovorin (LV) in patients with unresectable or metastatic biliary (Bili) and gallbladder (GB) carcinoma: A North Central Cancer Treatment Group (NCCTG) study. Proc ASCO. 2003; 22 1102
28 Kang Y K, Choi D W, Im Y H. et al . A phase III randomized comparison of neoadjuvant chemotherapy followed by surgery versus surgery for locally advanced stomach cancer. Proc ASCO. 1996; 15 215
29 Kato H, Udagawa H, Togo A. et al . A phase II trial of chemo-radiotherapy in patients with stage I esophageal squamous cell carcinoma: Japan Clinical Oncology Group study (JCOG9780). Proc ASCO. 2003; 22 1147
30 Kindler H L, Ansari R, Lester E. Bevacizumab (B) plus gemcitabine (G) in patients (pts) with advanced pancreatic cancer (PC). Proc ASCO. 2003; 22 1037
31 Köhne C H, Van Cutsem E, Wils J A. et al . Irinotecan improves the activity of the AIO regimen in metastatic colorectal cancer: Results of EORTC GI Group study 40 986. Proc ASCO. 2003; 22 1018
32 Lee J L, Kim S B, Jung H Y. et al . A single institutional phase III trial of preoperative chemotherapy with hyperfractionation radiotherapy plus surgery (CRT-S) versus surgery (S) alone for stage II, III respectable esophageal squamous cell carcinoma (SCC): An interim analysis. Proc ASCO. 2003; 22 1043
33 Leung T WT, Mo F, Leow C K. et al . Multicenter validation of the Chinese University Prognostic Index (CUPI) for hepatocellular carcinoma (HCC). Proc ASCO. 2003; 22 1040
34 Louvet C, Labianca R, Hammel P. et al . Gemcitabine versus GEMOX (gemcitabine + oxalipaltin) in non resectable pancreatic adenocarcinom: Interim results of the GERCOR/GISCAD Intergroup Phase III. Proc ASCO. 2003; 22 1004
35 Mal F, Perniceni H, Levard E. et al . Predictive factors of post operative early redux of oesophageal or cardial adenocarcinoma: A retrospective study in 100 patients. Proc ASCO. 2003; 22 1350
36 Mantravadi R VP, Fineberg N, Ansari A. et al . A phase Ii study of cisplatin, 5-fluorouracil (5-FU), radiation 8RT) and celecoxib in patients with resectable esophageal cancer 8EC): Preliminary results from the Hoosier Oncology Group (HOG). Proc ASCO. 2003; 22 1168
37 Moehler M H, Siebler J, Hoehler T. et al . Safety and efficacy of CPT11/FA/5-FU (ILF) versus ELF in previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction. Proc ASCO. 2003; 22 1034
38 Muro K, Ando N, Nishimaki T. A phase II study of nedaplatin and 5-fluorouracil in metastatic squamous cell carcinoma of the esophagus: The Japan Clinical Oncology Group (JCOG) trial (JCOG 9905). Proc ASCO. 2003; 22 1112
39 Nehls O, Oettle H, Hartmann J T. et al . Oxaliplatin plus capecitabine in advanced biliary system adenocarcinomas: A multicenter phase II trial. Proc ASCO. 2003; 22 1126
40 Rizk N, Akhurst R, Downey R J. et al . FDG PET scanning predicts tumor stage and survival in esophageal adenocarcinoma. Proc ASCO. 2003; 22 1085
41 Reyes-Vidal J, Gallardo J, Yanez E. et al . Gemcitabine (G) and cisplatin (C) in the treatment of patients (pts) with unresectable or metastatic gallbladder cancer: Results of the phase II GOCCHI study. Proc ASCO. 2003; 22 1095
42 Rocha-Lima C MS, Rotche R, Jeffery M. et al . A randomized phase 3 study comparing theefficacy and safety of gemcitabine (GEM) and irinotecan (I), to GEM alone in patients with locally advanced or metastatic pancreatic cancer who have not received prior systemic therapy. Proc ASCO. 2003; 22 1005
43 Ross P, Nicolson M, Cunningham D. et al . Prospective Randomized Trial Comparing Mitomycin, Cisplatin, and Protracted Venous-Infusion Fluorouracil (PVI 5-FU) With Epirubicin, Cisplatin, and PVI 5-FU in Advanced Esophagogastric Cancer. J Clin Oncol. 2002; 20 1996-2004
44 Scheithauer W, Schuell B, Dworan N. et al . Mitomycin C in combination with capecitabine or biweekly high dose gemcitabine in patients with advanced biliary tract cancer (ABC). Proc ASCO. 2003; 22 1059
45 Songun I, Keizer H J, Hermans J. et al . Chemotherapy for operable gastric cancer: results from the Dutch randomized FAMTX trial. The Dutch Gastric Cancer Group (DGCG). Eur J Cancer. 1999; 35 558-562
46 Stahl M, Wilke H, Walz M K. et al . Randomized phase III trial in locally advanced squamous cell carcinoma (SCC) of the esophagus: Chemoradiation with and without surgery. Proc ASCO. 2003; 22 1001
47 Stuart K, Eder J P, Proper J. et al . Phase II trial of irofulven in patients with unresectable hepatocellular carcinoma (HCC). Proc ASCO. 2003; 22 1107
48 Sumpter K A, Harper-Wynne C, Cunningham D. et al . Randomised multicenter phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer: Confirmation of dose escalation. Proc ASCO. 2003; 22 1031
49 Sun Y, Li H, Lin Z. et al . Phase I and pharmacokinetic study of nemorubicin hydrochloride (methoxymorpholino doxorubicin; PNU-152 243) administered with iodinated oil via hepatic artery (IHA) to patients (pt) with unresectable hepatocellular carcinoma (HCC). Proc ASCO. 2003; 22 1448
50 Tempero M, Plunkett W, Ruiz Van Haperen V. et al . Randomized phase II trial of dose intense gemcitabine by standard infusion vs fixed dose rate in metastatic pancreatic adenocarcinoma. Proc ASCO. 1999; 18 1048
51 Thongprasert S, Napapan S, Charoentum C. et al . Phase II study of gemcitabine plus cisplatin in biliary tract cancer. Proc ASCO. 2003; 22 1221
52 Treiber G, Heinrich U, Fostitsch P. et al . Palliative treatment of hepatocellular carcinoma (HCC) using octreotide, rofecoxib, or both. Proc ASCO. 2003; 22 1281
53 Tsuji A, Morita S, Horimi T. et al . A phase II study of 5-FU (CVI) and low-dose consecutive CDDP (LFP) therapy in advanced bile duct carcinoma. Proc ASCO. 2003; 22 1484
54 Webb A, Cunningham D, Scarffe J H. et al . Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol. 1997; 15 261-267
55 Yang T S, Chang W C, Lin Y C. et al . A phase II study of gemcitabine and cisplatin for patients with advanced hepatocellular carcinoma. Proc ASCO. 2003; 22 1351

PD Dr. Thomas Seufferlein

Abt. für Innere Medizin der Medizinischen Universitätsklinik Ulm

Robert-Koch-Straße 8

89081 Ulm